KJKyle Jerreld

Kyle Jerreld

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Kyle Jerreld has a total of 5 co-authors. Here are the top co-authors by number of shared publications:

  • Andrea De Pieri

    Regenerative, Modular & Developmental Engineering Laboratory (REMODEL), Biomedical Sciences Building, National University of Ireland Galway (NUI Galway), Galway, Ireland; Science Foundation Ireland (SFI) Centre for Research in Medical Devices (CÚRAM), Biomedical Sciences Building, National University of Ireland Galway (NUI Galway), Galway, Ireland; Proxy Biomedical Ltd., Spiddal, Galway, Ireland

    1 shared publication
  • Karin Wuertz-Kozak

    Department of Biomedical Engineering Rochester Institute of Technology Rochester New York USA

    1 shared publication
  • Keegan Ocorr

    Department of Biomedical Engineering, Rochester Institute of Technology (RIT), 106 Lomb Memorial Rd., Rochester, NY 14623, USA

    1 shared publication
  • Mikkael Lamoca

    Department of Public Policy Rochester Institute of Technology Rochester New York USA

    1 shared publication
  • Wolfgang Hitzl

    Research Office (Biostatistics), Paracelsus Medical University, Müllner Hauptstrasse 48, 5020 Salzburg, Austria

    1 shared publication

Latest Publications

  • Open Access

    Resveratrol Microencapsulation into Electrosprayed Polymeric Carriers for the Treatment of Chronic, Non-Healing Wounds

    by Andrea De Pieri, Keegan Ocorr, Kyle Jerreld, Mikkael Lamoca, Wolfgang Hitzl, Karin Wuertz-Kozak

    Chronic, non-healing wounds represent a challenging socio-economic burden, demanding innovative approaches for successful wound management. Resveratrol (RSV) represents a promising therapeutic candidate, but its therapeutic efficacy and clinical applicability have been hampered by its rapid degradation and/or depletion. Herein, RSV was encapsulated into poly(ε-caprolactone) (PCL) microparticles by electrospraying with the aim to prolong and preserve RSV’s release/activity, without affecting its therapeutic properties. Electrospraying led to the fabrication of spherical (2 to 10 μm in size), negatively charged (<−1 mV), and quasi-monodisperse (PDI < 0.3) microparticles, with 60% RSV release after 28 days. Microencapsulation of RSV into PCL prevented its photochemical degradation and preserved its antioxidant properties over 72 h. The RSV-PCL microparticles did not exhibit any cytotoxicity on human dermal fibroblasts. RSV released from the microparticles was biologically functional and induced a significant increase in collagen type I deposition. Furthermore, the produced RSV-PCL microparticles reduced the expression of inflammatory (IL-6, IL-8, COX-2) and proteolytic (MMP-2, MMP-9) mediators. Collectively, our data clearly illustrate the potential of electrosprayed polymeric carriers for the sustained delivery of RSV to treat chronic wounds.